# Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell Tumors

> **NCT03726281** · PHASE2 · WITHDRAWN · sponsor: **Hospital Beatriz Ângelo**

## Conditions studied

- Germ Cell Tumors

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03726281
- **Lead sponsor:** Hospital Beatriz Ângelo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-10-01
- **Primary completion:** 2019-06-30
- **Final completion:** 2019-06-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** End of Agreement between BMS and SGHL
- **Last updated:** 2019-08-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03726281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03726281, "Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03726281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*